Tevogen Bio, a clinical stage biotechnology company, announced that the FDA has cleared its Investigational New Drug application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes, allowing Tevogen Bio to initiate a clinical trial of its investigational COVID-19 treatment.
[Tevogen Bio (BusinessWire, Inc.)]
6445218
{6445218:nan}
apa
50
1
164463
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
